N-(2,6-dichloro-4-methyl-3-pyridinyl)-2-ethylamino-3-pyridinecarboxamide | 380379-04-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(2,6-dichloro-4-methyl-3-pyridinyl)-2-ethylamino-3-pyridinecarboxamide
• 英文别名: n-(2,6-Dichloro-4methyl-3-pyridinyl)-2-(ethylamino)-3-pyridinecarboxamide；N-(2,6-dichloro-4-methylpyridin-3-yl)-2-(ethylamino)pyridine-3-carboxamide
• CAS: 380379-04-4
• 化学式: C₁₄H₁₄Cl₂N₄O
• 分子量: 325.197
• InChiKey: PKTUMXXVOLICJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2,6-dichloro-4-methyl-3-pyridinyl)-2-ethylamino-3-pyridinecarboxamide 在 sodium hydride 作用下， 以 various solvent(s) 为溶剂， 生成 2-chloro-5,11-dihydro-11-ethyl-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
  参考文献：
  名称：

  Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes

  摘要：

  The major cause of viral resistance to the potent human immunodeficiency virus type 1 reverse transcriptase (RT) inhibitor nevirapine is the mutation substituting cysteine for tyrosine-181 in RT (Y181C RT), An evaluation, against Y181C RT, of previously described analogs of nevirapine revealed that the 2-chlorodipyridodiazepinone 16 is an effective inhibitor of this mutant enzyme. The detailed examination of the structure-activity relationship of 2-substituted dipyridodiazepinones presented below shows that combined activity against the wildtype and Y181C enzymes is achieved with aryl substituents at the 2-position of the tricyclic ring system. In addition, the substitution pattern at C-4, N-5, and N-11 of the dipyridodiazepinone ring system optimum for inhibition of both wild-type and Y181C RT is no longer the 4-methyl-11-cyclopropyl substitution preferred against the wild-type enzyme but rather the 5-methyl-11-ethyl (or 11-cyclopropyl) pattern. The more potent 8-substituted dipyridodiazepinones were evaluated against mutant RT enzymes (L100I RT, K103N RT, P236L RT, and E138K RT) that confer resistance to other non-nucleoside RT inhibitors, and compounds 42, 62, and 67, with pyrrolyl, aminophenyl, and aminopyridyl substituents, respectively, at the 2-position, were found to be effective inhibitors of these mutant enzymes also.

  DOI：

  10.1021/jm00024a010
• 作为产物：
  描述：

  2,6-二氯-4-甲基-3-氨基吡啶 以 various solvent(s) 为溶剂， 生成 N-(2,6-dichloro-4-methyl-3-pyridinyl)-2-ethylamino-3-pyridinecarboxamide
  参考文献：
  名称：

  Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes

  摘要：

  The major cause of viral resistance to the potent human immunodeficiency virus type 1 reverse transcriptase (RT) inhibitor nevirapine is the mutation substituting cysteine for tyrosine-181 in RT (Y181C RT), An evaluation, against Y181C RT, of previously described analogs of nevirapine revealed that the 2-chlorodipyridodiazepinone 16 is an effective inhibitor of this mutant enzyme. The detailed examination of the structure-activity relationship of 2-substituted dipyridodiazepinones presented below shows that combined activity against the wildtype and Y181C enzymes is achieved with aryl substituents at the 2-position of the tricyclic ring system. In addition, the substitution pattern at C-4, N-5, and N-11 of the dipyridodiazepinone ring system optimum for inhibition of both wild-type and Y181C RT is no longer the 4-methyl-11-cyclopropyl substitution preferred against the wild-type enzyme but rather the 5-methyl-11-ethyl (or 11-cyclopropyl) pattern. The more potent 8-substituted dipyridodiazepinones were evaluated against mutant RT enzymes (L100I RT, K103N RT, P236L RT, and E138K RT) that confer resistance to other non-nucleoside RT inhibitors, and compounds 42, 62, and 67, with pyrrolyl, aminophenyl, and aminopyridyl substituents, respectively, at the 2-position, were found to be effective inhibitors of these mutant enzymes also.

  DOI：

  10.1021/jm00024a010

文献信息

• Dipyridodiazepinone derivatives; synthesis and anti HIV-1 activity
  作者：Nisachon Khunnawutmanotham、Nitirat Chimnoi、Arunee Thitithanyanont、Patchreenart Saparpakorn、Kiattawee Choowongkomon、Pornpan Pungpo、Supa Hannongbua、Supanna Techasakul

  DOI：10.3762/bjoc.5.36

  日期：——

  Ten dipyridodiazepinone derivatives were synthesized and evaluated for their anti HIV-1 reverse transcriptase activity against wild-type and mutant type enzymes, K103N and Y181C. Two of them were found to be promising inhibitors for HIV-1 RT.

  合成了十种二吡啶基二氮杂环己酮衍生物，并针对野生型和突变型酶K103N和Y181C评估它们对HIV-1逆转录酶的抑制活性。其中有两种被发现是有希望的HIV-1 RT抑制剂。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：——

  公开号：US20020028807A1

  公开（公告）日：2002-03-07

  Provided are compounds of the general formula I: 1 wherein R 2 is selected from the group consisting of H, F, Cl, (C 1-4 ) alkyl, (C 3-4 ) cycloalkyl and CF 3 ; R 4 is H or Me; R 5 is H, Me or Et, with the proviso that R 4 and R 5 are not both Me, and if R 4 is Me then R 5 cannot be Et; R 11 is Et, cyclopropyl, propyl, isopropyl, or isobutyl; and is selected from the group consisting of: 2 and pharmaceutically acceptable salts thereof, as inhibitors of HIV reverse transcriptase, wild-type and several mutant strains.

  提供的是一般式I的化合物：其中R2从H、F、Cl、(C1-4)烷基、(C3-4)环烷基和CF3组成的群体中选择；R4为H或Me；R5为H、Me或Et，但R4和R5不能同时为Me，如果R4为Me，则R5不能为Et；R11为Et、环丙基、丙基、异丙基或异丁基；并选择自以下组合物：2和其药学上可接受的盐，作为HIV逆转录酶、野生型和几种突变株的抑制剂。
• [EN] NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS<br/>[FR] INHIBITEURS NON NUCLEOSIDIQUES DE TRANSCRIPTASE INVERSE
  申请人：BOEHRINGER INGELHEIM CA LTD

  公开号：WO2001096338A1

  公开（公告）日：2001-12-20

  Provided are compounds of general formula (I), wherein R2 is selected from the group consisting of H, F, Cl, (C¿1-4?) alkyl, (C3-4) cycloalkyl and CF3; R?4¿ is H or Me; R5 is H, Me or Et, with the proviso that R?4 and R5¿ are not both Me, and if R4 is Me then R5 cannot be Et; R11 is Et, cyclopropyl, propyl, isopropyl, or isobutyl; and Q is selected from the group consisting of (II), (III), (IV) and (V); and pharmaceutically acceptable salts thereof, as inhibitors of HIV reverse transcriptase, wild-type and several mutant strains.

  提供了一般式为(I)的化合物，其中R2从H、F、Cl、(C1-4)烷基、(C3-4)环烷基和CF3中选择；R4为H或Me；R5为H、Me或Et，但R4和R5不能同时为Me，如果R4为Me，则R5不能为Et；R11为Et、环丙基、丙基、异丙基或异丁基；Q从(II)、(III)、(IV)和(V)中选择；以及其药学上可接受的盐，作为HIV逆转录酶、野生型和几种突变株的抑制剂。
• Method and compositions for identifying anti-hiv therapeutic compounds
  申请人：Birkus Gabriel

  公开号：US20070190523A1

  公开（公告）日：2007-08-16

  The invention relates to methods and compositions for identifying compounds having therapeutic activity against human immunodeficiency virus (HIV).

  本发明涉及用于鉴定具有治疗人类免疫缺陷病毒（HIV）活性的化合物的方法和组合物。
• NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
  申请人：BOEHRINGER INGELHEIM (CANADA) LTD.

  公开号：EP1294720A1

  公开（公告）日：2003-03-26